 |
인쇄하기
취소
|
SymBio targets cancer patch market
Japanese company SymBio has landed a Korean partner for its novel transdermal patch for chemotherapy-induced nausea, the firm's first patch product with ambitions to steal a sizeable chunk of Korea's market.
The company has signed an exclusive distribution agreement with Yuhan Corporation, who will take care of commercializing the patch product in the Korean market.
The Japanese firm has...
The company has signed an exclusive distribution agreement with Yuhan Corporation, who will take care of commercializing the patch product in the Korean market.
The Japanese firm has...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.